# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce fracture healing problem
- describe MPC homing and differentiation
- discuss UPS regulation of OB differentiation
- introduce Btz as proteasome inhibitor
- describe Btz effects on OB and OC
- discuss limitations of Btz therapy
- highlight need for targeted bone delivery

## BRIEF SUMMARY OF THE INVENTION

- introduce compound of formula (I)
- define R1-R5 and L1-L3
- define Y, Z1-Z5, and A
- describe compound of formula (II)
- describe compound of formula (III)
- specify Y as —PO3(R1)2
- specify L1 as alkyl, aryl, or alkylaryl
- specify L2 and L3 as phenyl or alkyl chain
- specify A as C(═N) or C(═O)
- specify Z2 as O
- specify Z5 as certain structures

## DETAILED DESCRIPTION OF THE INVENTION

- introduce Bortezomib conjugates for bone formation
- describe conjugate properties and advantages
- outline methods for promoting bone formation
- summarize compositions for controlled local delivery

### Definitions

- define technical and scientific terms
- introduce articles "a" and "an"
- define "about" in measurable values
- define "abnormal" in organisms and cells
- define "disease"
- define "disorder"
- define "alleviated"
- define "patient", "subject", or "individual"
- define "pharmaceutical composition"
- define "therapeutic" treatment
- define "treatment" or "treating"
- define "effective amount"
- define "pharmaceutically acceptable"
- define "pharmaceutically acceptable salt"
- define "pharmaceutically acceptable carrier"
- define "effective amount" of delivery vehicle
- define "potency"
- define "efficacy"
- define "alkyl"
- define "heteroalkyl"
- define "heterocycloalkyl"

### DESCRIPTION

- introduce carbamate linkers
- describe advantage of labile linkers
- define conjugate
- list functional groups for linkers
- describe cleavable bonds
- explain influence of bond stability on Btz release
- describe embodiment with non-cleavable linker
- describe embodiment with slow Btz release
- describe embodiment with rapid Btz release
- describe influence of electronics on linker reactivity
- describe conjugation to dyes or fluorescent molecules
- describe synthesis of compounds
- define formula (I)
- describe R1, R2, R3, R4, L1, L2, L3, Y, Z1, Z2,
- describe Z3, Z4, Z5, R5, R6, R7, R8, R9, R10, R11
- describe R12, R13, R14, R15, R16, R17, R18
- define formula (II)
- define formula (III)
- describe embodiments of R1, R2, R3, R4, Z1, Z2, Y
- describe Notch inhibitors as therapeutic agents

### Preparation of the Compounds of the Invention

- describe general synthetic scheme
- conjugate phosphonate with diol
- join diol to boronic acid moiety
- form carbamate diol
- produce boronate ester
- discuss stereocenters and isomers
- prepare optically active forms
- describe use of N-oxides, crystalline forms, solvates, and salts
- discuss isotopically-labeled compounds and prodrugs

### Therapeutic Methods

- promote or induce bone formation
- treat diseases characterized by bone loss
- treat bone cancer
- promote bone formation at site in need
- reduce bone resorption
- inhibit inflammation and kill cancer cells

### Pharmaceutical Compositions and Administration

- define pharmaceutical compositions
- describe administration routes
- list formulation types
- detail unit dose definition
- describe active ingredient amounts
- list additional pharmaceutically active agents
- describe controlled-release formulations
- detail oral application formulations
- describe tablet preparation methods
- list tablet excipients
- describe granulating techniques
- detail melt granulation process
- describe parenteral administration formulations
- list parenteral formulation ingredients
- describe pulmonary administration formulations
- detail dry powder composition
- describe low-boiling propellants
- list additional ingredients

### Controlled Release Formulations and Drug Delivery Systems

- define sustained release
- describe delayed release and pulsatile release
- detail short-term and rapid-offset formulations

## EXAMPLES

- provide examples of the invention

### Example 1: Synthesis of BP-Btz1

- synthesize urethane diol 2
- synthesize BP-Btz1
- characterize BP-Btz1

### Example 2: Study of Osteoblast Regulation in TNF-Mediated Bone Loss

- discuss role of UPS-mediated protein modification in bone repair
- describe challenges of delivering drugs to bone
- discuss BP-drug conjugation technology
- present results of in vitro and in vivo studies of BP-Btz1

### Example 3: Study of Osteoblast Regulation in TNF-Mediated Bone Loss

- introduce knockout mice models
- describe bone fracture repair process
- motivate UPS-mediated cellular event in bone repair
- design and synthesize bone-targeted Bortezomib conjugates
- describe chemical design and synthesis of BT-Btz1
- describe chemical design and synthesis of BT-Btz2
- purify BT-Btz conjugates
- test bone-targeted Bortezomib in regulating osteoblasts and osteoclasts vitro
- determine effect of BT-Btz conjugates on OB differentiation and protein degradation in vitro
- examine effect of BT-Btz conjugates on OC formation and bone resorption in vitro
- discuss potential mechanisms of BT-Btz conjugates
- outline in vivo testing of BT-Btz conjugates
- describe statistical plan and data analysis

### Example 4: Protein Modification in Bone Cell Regulation

- hypothesize UPS inhibition promotes fracture healing
- observe ubiquitinated proteins in fracture calluses
- design, synthesize, and test bone-targeted Bortezomib conjugates in vitro
- synthesize two types of bone-targeted BP-Btz conjugates
- test conjugates' binding to bone slices and inhibition of OC function
- examine effects on OB differentiation
- design BP-Btz3 and BP-Btz5 with varied ring size
- synthesize BP-Btz3 and BP-Btz5
- purify BP-Btz3 and BP-Btz5
- design BP-Btz2, BP-Btz4, and BP-Btz6 with amide and amine stabilized boronate ester moieties
- synthesize BP-Btz2, BP-Btz4, and BP-Btz6
- purify BP-Btz2, BP-Btz4, and BP-Btz6
- design BP-Btz7-BP-Btz10 without amine stabilizing group
- synthesize BP-Btz7-BP-Btz10
- purify BP-Btz7-BP-Btz10
- examine bioactivity of BP-Btz conjugates on OB differentiation and OC formation in vitro
- examine bone-targeted Bortezomib conjugates on bone volume and regeneration in vivo
- examine efficacy of BP-Btz for prevention of OVX-induced bone loss
- examine efficacy of BP-Btz conjugates on bone fracture repair in aged mice

### Example 5: Bone-Targeted Bortezomib Prevents OVX- and Myeloma-Induced Bone Loss with Less Systemic Adverse Effects More Effectively than Bortezomib

- introduce BP-Btz1
- describe experiments on BP-Btz1
- summarize results of BP-Btz1 experiments

### Example 6: Synthetic Examples

- introduce synthesis of ((((2-(2-((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine
- describe step 4/5 of synthesis
- describe step 6 of synthesis
- describe step 7/8 of synthesis
- introduce synthesis of ((2-(2-((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine
- describe step 4/5 of synthesis
- describe step 6 of synthesis
- describe step 7/8 of synthesis
- introduce synthesis of ((4-(2-((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine
- describe step 4 of synthesis
- describe step 5/6 and 7/8 of synthesis

